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Presentation of Case
Dr Bhavani Puskur (Infectious Diseases (ID) fellow): 
A 54-year-old male active smoker with a history of chronic 
obstructive lung disease (COPD) on 2 L/min of home oxygen 
and human immunodeficiency virus-1 (HIV) on antiretroviral 
therapy with a recent CD4 count of 482 (26%) cells/cc and a 
suppressed viral load, presented to the Emergency Room (ER) 
of University of Louisville Hospital with a cough productive of 
thick, yellow phlegm, dyspnea for 4 days and chest tightness 
for one day.  He complained of having a sore throat, rhinorrhea 
and nasal congestion during the previous week.  He had been 
using his inhalers at home without significant relief.  He denied 
fever or chills.  He had been to the ER multiple times with 
worsening dyspnea and nonproductive cough, which improved 
with prednisone and bronchodilators.  He declined frequent 
admission, but this was his third visit to the ER in the last two 
days; each via emergency medical services transportation.
In the ER, his temperature was 36.6°C, blood pressure was 
210/141 mmHg, heart rate was 120 beats/min, and respiratory 
rate 16/min.  His oxygen saturation was 98% while wearing a 
non-rebreather mask.  On physical examination, there was 
no pharyngeal erythema or exudate and sinuses were non-
tender. He had pursed lip breathing with significant inspiratory 
wheezing.  After administration of a breathing treatment and 
steroids, there was improved aeration throughout all lung fields 
with decreased, but still diffuse, expiratory wheezing.  A chest 
X-ray was obtained. (Figure 1)  His electrocardiography was 
unchanged, and troponins were negative.  He was admitted to 
the Intensive Care Unit (ICU) for use of non-invasive ventilation. 
Diagnostic Approach
Dr. Viswanathan Nagarajan (ID fellow):  The patient’s 
symptoms were acute in onset with shortness of breath, cough 
and yellow sputum production, and an episiode of chest tightness, 
with a history of COPD and active smoking.  The differential 
diagnoses at this point are numerous including resipiratory 
viruses (e.g., influenza A and B, rhinovirus, respiratory syncytial 
virus (RSV)), and bacteria including Hemophilus influenzae, 
Streptococcus pneumoniae, and Moraxella catarrhalis). 
The chest tightness which occurred suddenly with continued 
worsening of oxygenation could be from pneumonia, bronchitis 
or fatigue associated with use of accessory muscles.  Although, 
the chest X-ray does not reveal a consolidation, I note a lack of 
vascular markings on the right upper part of the thorax when 
compared to the left side.  Even though a high blood pressure 
and a lack of a pleural line argue against the possibility 
of a pneumothorax, my concern is that this patient has a 
pneumothorax of the right lung in view of his symptoms of acute 
onset of chest pressure, worsening oxygenation and tachycardia. 
Frequently, in small pneumothoraces, physical exam and blood 
pressure may be normal.
After reviewing the chest X-ray, my differential diagnoses take 
a path towards pneumonia causing pneumothorax, rupture 
of a bulla from COPD, any cavity producing organism like 
Mycobacterium avium intracellulare or M. tuberculosis. 
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Figure 1 Portable chest X-ray taken at admission
Bacterial etiologies like Klebsiella pneumoniae, Staphyloccocus 
aureus and Pseudomonas aeruginosa are capable of producing 
necrotizing pneumonia.  Finally, fungal causes like Aspergellus 
fumigatus and other fungal lesions (e.g., Histoplasma 
capsulatum, Blastomyces dermatitidis and Cryptococcus 
neoformans) could also produce a cavity and cause a 
pneumothorax.
Since there is no cavity seen on the chest X-ray, my concern 
is a possibility of Pneumocystis jiroveci pneumonia (PCP). 
However, his adequate CD4 and undetectable viral load may 
deter one from thinking he has PCP.  
Dr. Veronica Corcino (ID fellow): During the initial 
evaluation of a patient with the mentioned symptoms, it is of 
utmost importance to identify the possible causes of acute 
respiratory difficulty.  Some elements of the history and physical 
exam may lead us to favor an infectious disease, a vascular 
problem or a malignancy.  His previous empiric steroid use may 
have contributed to iatrogenic immunosuppression.  Since he 
is HIV-positive, we need to broaden our diagnostic infectious 
considerations.  The arterial blood gas results are compatible 
with a respiratory acidosis with some metabolic compensation. 
Also, the Arterial-alveolar gradient is elevated to 389 (his 
normal should be <18), representing a severe hypoxemic 
drive.  The most common infectious causes of his respiratory 
distress are viral infections, such as parainfluenza, influenza, 
adenovirus, coronavirus and RSV; atypical bacteria, such as 
Mycoplasma pneumoniae, Chlamydophilia pneumoniae and 
Legionella pneumophila; mycobacterial infections and common 
bacteria including S. pneumoniae and H. influenzae.  Also, with 
the decrease in vascularity on the chest X-ray, I agree we need to 
consider a pneumothorax, and possibly due to PCP.  
To establish a definitive diagnosis, it is imperative to initially 
perform a chest CT scan, viral respiratory panel, atypical 
respiratory panel, urine Legionella and Streptococcal antigen 
tests, blood cultures and sputum cultures.  Also, cultures from a 
bronchoscopic sample would be valuable.  
Dr. Srikanth Ramachandruni (ID fellow):  I was thinking 
he could possibly have a pneumatocele or pneumothorax.  But if 
that is the case, I am not sure why ID was consulted.  
Dr. Julio Ramirez (Chief of ID): We are missing some 
information.  For this patient with a history of COPD, an older 
film is needed to compare if any of the abnormalities we see now 
are new or chronic.
Dr. Ramachandruni: Yes, that would help.  It would also 
be good to know if he has been on multiple recent courses of 
prednisone.  If so, he may be immunosuppressed from that 
perspective.  If his CD4 cells were nonfunctional, although 
above 200 cells/µL, then that might expand the differential, 
too.  Given that we know he was in the ER, was discharged and 
returned within a few hours, I am thinking of an acute event 
occurred like a pneumothorax.  There are lung markings that do 
not extend peripherally on the right as far as they do on the left, 
which could be evidence of a pneumothorax.  What is the most 
common organism that can produce a pneumothorax?  PCP. 
And, I agree with the causes of pneumonia in a COPD patient 
mentioned by Drs. Viswanathan and Corcino; multiple viruses, 
as well as H. influenzae, S. aureus, M. tuberculosis, and other 
bacteria.
Dr. Ramirez: So, what I heard was a possible pneumothorax 
due to Pneumocystis, and I do not have a problem with that.  I 
have a problem with all of the organisms you all discussed that 
can cause pneumonia in an HIV patient when I do not see any 
pulmonary infiltrate here.  I agree with your assessment of the 
lack of lung markings in the periphery on the chest X-ray.  If it is 
not a pneumothorax then there could be bullae present because 
of COPD.  To emphasize, the patient may have a pneumothorax 
and if so, it could be due to Pneumocystis, and Pneumocystis 
may be present without an infiltrate.  If you say S. aureus or 
tuberculosis caused an abscess that eroded into the pleural space 
and caused a pneumothorax, then you have to have an infiltrate 
and there is no infiltrate.  What other infectious disease might 
this patient have that would prompt a consult?
Dr. Barbara Wojda (ID faculty): ID may have been 
consulted because this patient has HIV.
Dr. Martin Raff (ID Faculty-Emeritus):  Another thing 
is the isolation of Aspergillus from the sputum.  If he is having 
bronchospasm that is progressively worsening, it may be a 
bronchopulmonary Aspergillosis.  The lack of eosinophilia goes 
against that, but you do not necessarily have to have systemic 
eosinophilia to have allergic pneumoconiosis.  And I do not 
know what his sputum showed in terms of eosinophils.
Dr. Ramirez: We have also seen patients with asthma 
admitted with pneumococcal bacteremia from the oropharynx, 
but it is more common in pediatrics.  
Dr. Raff: Radiologically, there is obvious, long-term 
emphysema – he has widened interspaces.  In patients with 
COPD, infiltrates might not appear as they do in a normal lung. 
There is something in the posterior basal segment of the right 
lower lobe, but it is not very impressive.  I do not see a pleural 
line to support a pneumothorax.  There is something vague, a 
circular density, inside the right heart border.  Again, this film is 
difficult to interpret.
Dr. Anupama Raghuram (ID Faculty): You fellows 
primarily mentioned pneumocystis, but it was not as high on 
my differential.  Having said that, we have seen patients with 
a suppressed HIV viral load and an increased CD4 count and 
percentage who had prophylactic medication for PCP that was 
discontinued too soon.  We are supposed to wait three months 
before we discontinue that prophylaxis.  But this patient, who I 
am sure has had multiple COPD exacerbations, had recurrent 
symptoms and rhinorrhea for a week, then got a little better 
over the last four days with bronchodilators.  He did not really 
get better – because he came back in 14 hours with much 
worse symptoms.  If I look at this presentation, he started out 
with something viral and then developed an infiltrate due to a 
superimposed bacterial infection.
Dr. Ramirez:  So, if this patient has COPD and he is coughing, 
then what is the difference between just an exacerbation and a 
complicating pneumonia?  The presence of a new infiltrate.  So, 
if he has a positive polymerase chain reaction (PCR) test for 
Influenza, Mycoplasma, Legionella or he has a positive sputum 
culture for pneumococcus, S. aureus or other, and he does not 
have pneumonia, then we know his airway is colonized, and 
have to wonder if this caused his exacerbation or not.  
Dr. Puskur: The lungs are hyperinflated.  There are no focal 
airspace or interstitial opacities, pleural effusion or evidence 
for pneumothorax.  The cardiomediastinal contours are within 
normal limits.  Finally, these were redemonstrated findings of 
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chronic emphysema without acute cardiopulmonary process 
compared to a previous film. (Figure 2)
Figure 2 Portable chest X-ray taken 6 weeks prior to admission.
Dr. Ramirez: So, there were no new changes on the chest 
X-ray and these were all chronic changes.
Dr. Puskur: Yes.  The patient was admitted to the ICU where 
he was placed on non-invasive ventilation, and then he was 
intubated and mechanically ventilated.  His influenza and 
pneumococcal vaccines were up to date.  He was started on 
empiric levofloxacin.  A respiratory viral panel was negative 
except for parainfluenza-3 virus (PIV-3). (Table 1)  An influenza 
antibody was high at 1.74 (normal ≤1.11).  
Table 1 Results of the respiratory viral panel
Dr. Ramirez: Why are we ordering antibodies for influenza?! 
We have to discuss this with the laboratory.  If you have a PCR 
for influenza virus, why do we want to get influenza antibodies? 
Dr. Puskur:  This was before ID consultation.  Additionally, 
blood cultures were negative.  The Legionella and Streptococcal 
urine antigens were negative.  The sputum culture grew H. 
influenza β-lactamase negative, and S. pneumoniae, which 
was sensitive to ceftriaxone and was intermediately resistant to 
penicillin with a minimal inhibitory concentration of 4 dilutions.
Dr. Ramirez:  An MIC of 4 – we have not seen this.  Regardless, 
this is a COPD exacerbation and now that we do PCRs, I go back 
to the idea that we are getting a PCR for everything now.  The 
question is, and we are learning, “What is the microbiome of 
the respiratory tract?”  I used to teach with Dr. Raff years ago 
that below the glottis the airway was sterile in a normal person. 
Now we know that below the glottis in a normal person there 
are millions of bacteria and viruses.  All of the lung is filled with 
bacteria and viruses that we previously were not able to detect 
with culture and we were not aware of.  The microbiome of the 
respiratory tract - the bacteriome of the lung, the virome of the 
lung - comprises bacteria and viruses that we normally have 
in the lung.  We are learning that our entire airway is full of 
bacteria that we did not previously recognize were there.  We 
already knew this of the gastrointestinal tract.  My point is that 
now that we have started doing PCRs from the respiratory tract, 
we are finding, for example, parainfluenza.  Is parainfluenza 
part of the normal flora of the respiratory tract in a normal 
person?  I do not know.  Is parainfluenza part of the normal flora 
in someone with COPD?  I do not know, but chances are, the 
answer is, “Yes.” 
We have started doing all these PCRs in all these patients and we 
are finding everything in every patient.  I am exaggerating, but 
the problem is that we are going to start finding, for example, 
parainfluenza, H. influenza and pneumococcus.  Are we going 
to treat every time we find a positive PCR from the respiratory 
tract?  This is going to be the new ID frontier.  This is the new 
antimicrobial stewardship management because the FDA is 
ready to approve more tests.  We already have the viral panel 
with 15 PCRs.  A patient has whatever virus is in the airway. 
This patient has COPD.  Are the organisms detected his normal 
flora?  Or is the acute exacerbation due to one of the organisms? 
How are you going to know?  At least until now, we had a culture 
that requires 103 or 104 organisms to be significant, so having a 
negative culture meant that there were not enough organisms 
to cause disease.  But now with the PCR, everybody is going to 
be positive.  
When we say that 20-30% of the population has pneumococcus 
colonized in the oropharynx, it is because you can culture 20-
30%.  We looked at patients in our database with community-
acquired pneumonia with negative cultures, and our colleagues 
in the Clinical Translational & Research Building figured out 
the microbiome.  They found Streptococcal pneumoniae in 9 
out of 10 cultures.  So, if you do a PCR from a bronchoscopy 
sample, you find the pneumococcus in nearly everybody.  Does 
this mean that they have pneumococcal pneumonia or does this 
mean that the pneumococcus is part of their normal flora?  
In this patient with a COPD exacerbation, I imagine someone 
gave him oxygen, which led to CO2 retention leading to 
hypoventilatory respiratory failure and metabolic acidosis 
necessitating intubation and mechanical ventilation.  An 
endotracheal aspirate was performed and the results were 
H. influenza, pneumococcus resistant to penicillin and 
parainfluenza.  And what did we do?  The patient was 
probably placed on ceftriaxone.  It is good that we did not 
find Pseudomonas, but only because a PCR for that was not 
ordered.  I’m sure, as a COPD patient, he carries Pseudomonas 
in his airway.  If we had a positive PCR for Pseudomonas, what 
would you do?  Put him on meropenem for 10 days for a COPD 
exacerbation?  In the past, we would not have known what 
everyone was colonized with, and so we would treat empirically 
with penicillin or tetracycline.  But soon, we will walk around 
the hospital and everybody will be on a carbapenem – because 
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Influenza A    Negative   
Influenza A H1  Negative  
Influenza A H3  Negative 
Influenza A 2009 H1N1    Negative 
Influenza B    Negative  
Parainfluenza-1  Negative 
Parainfluenza-2  Negative 
Parainfluenza-3  Positive   
Parainfluenza-4  Negative 
Human Metapneumovirus  Negative 
Coronavirus 229E Negative 
Coronavirus HKU1 Negative 
Coronavirus NL63  Negative 
Coronavirus OC43 Negative 
Human Rhinovirus Negative 
Adenovirus B/E  Negative 
Adenovirus C  Negative 
RSV-A Negative 
RSV-B  Negative 
 
everybody will have an extended-spectrum β-lactamase 
infection in some place.  This is what is coming for us.  
We are always going to get something from PCR tests for 
bacteria and viruses in patients without a pulmonary infiltrate. 
To me, this is a critical issue.  There is not a pulmonary infiltrate 
in this patient.  What do we do?  My suggestion would be until 
we know any better, I would not treat.  Now, do we need to treat 
COPD exacerbations? That is a different question. 
To summarize, consider the patients we enroll for pneumonia. 
Some fulfill the criteria for pneumonia and are treated as such, 
but eventually it is clear that they just have COPD.  Initially, 
we start ceftriaxone and azithromycin.  In two days the 
patient looks and feels better and the sputum culture grows 
multidrug-resistant Pseudomonas.  By that time, we know the 
Pseudomonas is colonization because they got better without 
antibiotic coverage for it.  This is colonization, and we just 
continue with the cephalosporin and macrolide.  We always 
look at the patient first.  Now, with these new tests, the patient 
is going to arrive to the hospital.  You are going to know in 
three hours that you have a multidrug-resistant Pseudomonas 
or Klebsiella with a carbapenemase because of a PCR for Gram 
negatives and a PCR for resistance genes.  Are you going to 
continue with the ceftriaxone and azithromycin, or are you 
going to give meropenem or colistin?  This is going to be the 
issue that we are going to face.  
We have three organisms and a COPD exacerbation - what do 
you think is the cause of the COPD exacerbation?  
Dr. Puskur: It could be PIV-3 and the copathogens – H. 
influenza and S. pneumoniae.  PIV-3 is the most prevalent 
serotype in both children and adults and is associated with 
pneumonia and bronchiolitis; bronchiolitis is typically only 
seen in children.  Number 3 is the least predictable PIV and 
is endemic, but outbreaks do occur in the spring [1,2].  In 
the United States, PIV-1 usually causes outbreaks biennially 
during the fall of odd-numbered years [1].  PIV-2 occurs in 
annual epidemics in the fall [1].  PIV-1 and -2 are detected 
less frequently in adults and are usually associated with upper 
respiratory tract infection, although lower tract disease has been 
described [4].  PIV-4 usually causes mild upper respiratory tract 
infection in both adults and children.  Seasonal patterns of PIV-4 
infections have not been established since the disease is usually 
mild and the virus is difficult to detect.  So I was thinking this is 
parainfluenza virus causing an exacerbation with superimposed 
H. influenzae or pneumococcus.
Dr. Ramirez: Again, I cannot disagree or agree, but I can tell 
you it could be PIV-1, -2, all of the above or none of the above. 
The way that you state this, the patient will need antibiotic 
therapy.  The point I am trying to make is that this patient is 
colonized with all these pathogens.  
Dr Raff: Were there any white cells in the sputum smear?
Dr Ramirez: When we look at the literature on COPD 
exacerbation, people are still using the Anthonisen criteria for 
antibiotic therapy [4,5].  And we go back to the idea to which 
Dr Raff eluded.  Are there white blood cells?  What is the quality 
of the sputum?  Has the sputum increased?  Has the sputum 
changed from yellow to green?  You say, “This is pre-history,” 
but these are the elements we use to see if we have an active 
infection.  If not, a person does not need antibiotics.  
Dr Puskur: He had thick sputum when he came in.
Dr Ramirez: To evaluate the cause of the thick sputum, we 
do a Gram stain to evaluate if the bacteria and viruses that are 
always going to be living in the airways of patients – always 
living in us – are causing disease.  
Dr. Raff: And the thing about it is, you can never be certain of 
anything, the overwhelming odds here are that this gentleman 
does not have infection that needs treatment.  Is that 100%?  Of 
course not.  But, we make clinical decisions all the time.  
Dr. Ramirez: Then you evaluate the risks versus the benefits. 
The possibility of infection is low.  If I treat this patient’s 
penicillin-intermediate S. pneumoniae, I will have to use high-
dose ceftriaxone.  The patient is in the unit on a ventilator.  Do 
I treat?  Well, I probably wait and see.  The advantage of having 
the patient in the hospital is being able to check him every day. 
This is going to be the balance.  I can tell you with all this new 
technology there is going to be so much overuse of antibiotics. 
The antimicrobial stewardship team will be very busy, and we 
will all be very busy.  We need to define when we are going to 
stop antibiotics, and when it will be appropriate to wait and re-
evaluate.
Dr. Puskur: The patient was treated empirically with 
levofloxacin, which was continued for one week.  
Anatomical Diagnosis
COPD exacerbation with colonization due to parainfluenza-3, 
Streptococcus pneumoniae and Hemophilus influenzae.
This case was presented at the University of Louisville Division 
of Infectious Diseases Patient Management Conference.
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